Figures & data
Table 1. Subject disposition and summary of exclusionsa from the per-protocol immunogenicity populations
Table 2. Summary of anti-HPV cLIA seropositivity percentages by vaccination group (per-protocol populationa)
Table 3. Summary of anti-HPV geometric mean titers at 1 month post-dose 3 by vaccination group (per-protocol populationa)
Table 4. Adverse event summary (days 1 to 15 following any vaccination visit) - all vaccinated subjects by age group